De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies-Reference-Cited by-同舟云学术

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

Published:2018-04-02 Issue:7 Volume:18 Page:1783-1789
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Bray R. A.¹,Gebel H. M.¹,Townsend R.²,Roberts M. E.²,Polinsky M.²,Yang L.²,Meier-Kriesche H.-U.²,Larsen C. P.¹

Affiliation:

1. Emory University; Atlanta GA USA

2. Bristol-Myers Squibb; Lawrenceville NJ USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajt.14721/fullpdf

Reference13 articles.

1. A phase III study of belatacept-based immunosuppression regimens vs cyclosporine in renal transplant recipients (BENEFIT study);Vincenti;Am J Transplant,2010

2. A phase III study of belatacept vs cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study);Durrbach;Am J Transplant,2010

3. Belatacept and long-term outcomes in kidney transplantation;Vincenti;N Engl J Med,2016

4. Long-term outcomes in belatacept- vs cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study;Durrbach;Am J Transplant,2016

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Rejection After Kidney Transplantation;Transplantation;2024-08-28

2. HLA Genotype Imputation Results in Largely Accurate Epitope Mismatch Risk Categorization Across Racial Groups;Transplantation Direct;2024-06-20

3. Use of a Belatacept-based Immunosuppression for Kidney Transplantation From Donors After Circulatory Death: A Paired Kidney Analysis;Transplantation Direct;2024-04-11

4. Exploring Costimulatory Blockade-Based Immunologic Strategies in Transplantation: Are They a Promising Immunomodulatory Approach for Organ and Vascularized Composite Allotransplantation?;Journal of Personalized Medicine;2024-03-20

5. Marginal Zone B Cells Are Necessary for the Formation of Anti-donor IgG After Allogeneic Sensitization;Transplantation;2024-02-16